Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Techniques & Tools

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Authors / Stephanie Vine

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

  • Contributions

Understanding the H5N1 Threat

February 3, 2025

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

4 min read

Understanding the H5N1 Threat

The Final Frontier?

December 1, 2014

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

0 min read

The Final Frontier?

Access All Areas

December 1, 2014

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

0 min read

Access All Areas

Battle of the Superbugs

December 1, 2014

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

0 min read

Battle of the Superbugs

Care to ‘Patent Dance’?

December 1, 2014

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

0 min read

Care to ‘Patent Dance’?

Regulators Target Ebola

December 1, 2014

Will FDA fast review and voucher incentives make a difference?

0 min read

Regulators Target Ebola

Dosing to Circadian Rhythm

December 1, 2014

Could medicines be made more effective with better timing?

0 min read

Dosing to Circadian Rhythm

Endolysins Vs MRSA

December 2, 2014

Micreos, a biotech based in the Netherlands, has launched the first endolysin registered for human use against methicillin-resistant Staphylococcus aureus. What is an endolysin? Micreos describes it as a “bacteria-killing enzyme” that originates from bacteriophages. We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out more.

0 min read

Endolysins Vs MRSA

Making European Regulations Work

December 2, 2014

Pathways designed to bring medicines to market faster in Europe are not delivering the goods

0 min read

Making European Regulations Work

Side Effects and Supercomputers

December 2, 2014

A group of researchers have used supercomputers to link proteins to drug side effects (1). Could this computational model be more predictive than current statistical methods?

0 min read

Side Effects and Supercomputers

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.